Articles tagged with Agonists
A cohort study investigates the association between bariatric surgery and preoperative use of GLP-1 receptor agonists. The results show a significant positive correlation between preoperative GLP-1 RA use and weight loss outcomes after surgery.
Researchers at the University of Pennsylvania and Chinese University of Hong Kong created TD3B, an AI framework guiding peptide generation toward candidates predicted to have a desired effect. The tool predicts binding likelihood and determines activation or deactivation of associated cellular machinery.
A secret shopper study found that online prescription vendors for GLP-1 receptor agonists often lack clinician interaction, relying on patient-reported questionnaires. This may lead to prescriptions being issued without important clinical and social history, compromising patient safety.
A recent study published in JAMA Otolaryngology–Head & Neck Surgery reveals a higher incidence of smell and taste disturbances among GLP-1 RA users. The findings underscore the importance of regular monitoring and awareness to mitigate these adverse effects.
A study found that adding orfglipron to titrated insulin glargine significantly improved glycemic control and body weight in participants with type 2 diabetes. The treatment did not increase the risk of hypoglycemia, compared to placebo.
Patients described GLP-1 RA therapy as a facilitator of lifestyle change, highlighting the need for standardized guidelines on patient education and clinical support. The quality of care was highly variable, leading to potential expectation management issues around adverse effects and long-term management.
A study found a significant decrease in metabolic bariatric surgery utilization between 2022 and 2024, with a 34.1% drop, while glucagon-like peptide-1 (GLP-1) use increased by 140.4% during the same period. This trend may continue due to growing prescribing of GLP-1s.
A retrospective cohort study examining over 840,000 breast cancer patients found a potential link between GLP-1 RA use and improved outcomes among obese or diabetic patients. GLP-1 RAs were associated with lower risk of death and recurrence over a 10-year follow-up period.
A cohort study found a potential association between GLP-1 RA use and improved survival rates among obese breast cancer patients with related metabolic conditions. Further evaluation of GLP-1 RA therapy in randomized clinical trials is warranted based on these findings.
A large cohort study found a modestly increased risk of nonarteritic anterior ischemic optic neuropathy associated with GLP-1 receptor agonist use. In contrast, SGLT2 inhibitor use was not linked to an increased risk. The findings warrant heightened vigilance for GLP-1 RA users.
A lower semaglutide price could generate savings that offset the cost of treating an additional 550,000 to 3.6 million Medicare beneficiaries eligible for expanded obesity-indication coverage. This voluntary price agreement may lead to substantial savings for Medicare spending on semaglutide treatment.
A meta-analysis of GLP-1 receptor agonist studies found potential safety signals for gastrointestinal side effects, while some evidence suggested a link to reduced respiratory disease risk. Further research is needed to confirm the latter association.
A post hoc analysis found that tirzepatide was associated with a lower incidence of a broad composite cardiovascular and kidney endpoint. The study compared tirzepatide with dulaglutide in patients with diabetes and established cardiovascular disease.
Continuing GLP-1/GIP agonists before upper endoscopy increased clinically significant residual gastric volume, but did not elevate adverse event risk. Clear liquids the day prior to the procedure may mitigate this risk.
Patients with type 2 diabetes and brain metastases who used GLP-1 receptor agonists showed a significant reduction in all-cause mortality. The use of these medications was associated with reduced neuroinflammation, preservation of the blood-brain barrier, and lowered oxidative stress and mitochondrial dysfunction.
A large cohort study found that fewer than 1 in 4 adults with overweight or obesity without diabetes remained on GLP-1RA treatment after 12 months. Treatment switching between GLP-1RA agents was common, reflecting active therapy management and the emergence of new formulations and weight management agents.
A new study reveals that STING agonists can directly trigger tumor cell death in nervous system cancers by activating an intrinsic molecular pathway inside cancer cells themselves. The research identifies HMGN2 as a key candidate promoting apoptosis and suppressing tumor growth.
A low-cost digital intervention increased expectation to adopt health behaviors among adults using GLP-1RAs, with effects persisting for 2 weeks. The written microsteps intervention plus short video boosters may play a role in promoting sustained behavior change.
A novel plant-based approach uses lettuce chloroplasts to produce functional GLP-1 peptides, paving the way for more affordable and better-tolerated oral medications. This method bypasses hurdles such as manufacturing cost, delivery system, and side effects associated with conventional approaches.
Semaglutide and tirzepatide prescriptions increased dramatically between 2018 and 2025, while MBS use rates declined substantially starting in 2023. Recent shifts in MBS use may be more pronounced in certain patient subgroups, such as those seeking sleeve gastrectomy or with lower BMIs.
A systematic review and meta-analysis found GLP-1 RAs produce significant weight loss across various subpopulations, including women who show improved outcomes compared to men. These findings have implications for clinical decision-making.
A new study finds that a novel GLP-1 receptor agonist, Exendin-4-Phe (Ex-Phe-1), preserves glycemic control while reducing malaise and vomiting behaviors in preclinical models. The compound uses biased agonism to selectively activate certain signaling pathways, achieving desired effects without triggering others.
A cohort study found combined GLP-1RA and progestin therapy reduces endometrial cancer risk in women with benign uterine pathology or endometrial hyperplasia. The study suggests potential benefits of this treatment approach for nonmalignant uterine diseases.
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly lowers risks of limb events, cardiovascular events, all-cause mortality, and kidney disease progression compared to dipeptidyl peptidase-4 inhibitors in patients with diabetes. GLP-1 RAs are preferred for secondary prevention in this high-risk population.
After initiating GLP-1 receptor agonists, consumers showed a decrease in ultraprocessed foods and an increase in protein, while purchasing fewer calories, sugars, and saturated fats. These modest changes may have significant population-level effects given increasing GLP-1RA use.
A comparative effectiveness study found that SGLT2 inhibitors were associated with a lower risk of chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists. These findings suggest that SGLT2 inhibitor treatment may be an effective strategy for preventing kidney disease in individuals with type 2 diabetes.
Both bariatric surgery and semaglutide treatment were associated with significant fat mass loss, moderate fat-free mass loss, and an improved FFM to fat mass ratio. These findings support interventions aimed at preserving muscle mass while promoting weight loss.
The study found that GLP-1 receptor agonists are increasingly used for postpartum weight loss in overweight women without a documented diabetes diagnosis. The primary indication for use was weight reduction, suggesting a potential shift in treatment guidelines.
A study found that women with obesity who stopped using GLP-1 receptor agonists experienced more gestational weight gain and a higher risk of preterm delivery, gestational diabetes, and hypertensive disorders. The research suggests that discontinuation of these medications may impact pregnancy outcomes.
Withdrawal of tirzepatide after 36-week treatment led to 25% or greater weight regain in most participants within a year, reversing initial cardiometabolic parameter improvements. Continued obesity treatment is crucial for sustained benefits.
A cohort study found that GLP-1 receptor agonist use was associated with a reduced risk of developing nonexudative AMD, but not progression to exudative AMD in individuals with nonexudative AMD. This study may inform future randomized trials evaluating the ocular effects of GLP-1RAs in nondiabetic populations.
This study found that GLP-1RAs and SGLT2is offer the greatest cardiovascular benefits for adults with type 2 diabetes. The magnitude of benefit depends on baseline age, atherosclerotic cardiovascular disease, heart failure, and kidney impairment.
A cohort study found that 40% of GLP-1RA orders were not filled, with lower rates among Non-Hispanic Black and Hispanic patients. These disparities may be attributed to differences in insurance coverage, GLP-1RA use, or cost thresholds.
Prior authorization for glucagon-like peptide-1 receptor agonists (GLP-1RAs) became near universal, leading to substantial out-of-pocket costs. Out-of-pocket costs for GLP-1RAs rose significantly from 2020 to 2025, affecting many high-cost drugs.
A binational study found nearly 6 in 10 US adults and 3 in 10 Japanese adults discontinued semaglutide within 12 months of treatment. Patients with established cardiovascular disease and chronic kidney disease had higher discontinuation rates, highlighting the need for alternative treatments.
Metabolic bariatric surgery shows promise as a cost-effective weight loss option for class II and III obesity patients. The study found bariatric surgery resulted in greater weight loss compared to GLP-1 receptor agonists.
A systematic review and meta-analysis of 18 trials found GLP-1 RAs significantly improved glycemic and weight outcomes in children and adolescents with type 2 diabetes or obesity. However, gastrointestinal adverse effects warrant attention in long-term management.
A cohort study found GLP-1 RAs offer body mass index-dependent cardiovascular benefits and consistent kidney protection for type 2 diabetes patients. The study suggests BMI stratification is crucial for guiding treatment decisions.
A retrospective cohort study found that GLP-1 receptor agonists may reduce overall cancer risk, including lower risks of endometrial and ovarian cancers, among patients with obesity or overweight. However, these medications may also increase the risk of kidney cancer, highlighting the need for longer-term follow-up.
Cohort study finds GLP-1 receptor agonist use associated with modestly increased risk of incident diabetic retinopathy; however, those with preexisting DR experience fewer sight-threatening complications. Regular screening and monitoring recommended for all T2D patients on GLP-1 RAs.
A study found that semaglutide and liraglutide use are associated with a higher risk of nonarteritic anterior ischemic optic neuropathy in older patients with type 2 diabetes. The GLP-1 receptor agonists showed varying levels of risk, with liraglutide posing the greatest threat.
A recent study published in JAMA Network Open found that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment was associated with reduced all-cause mortality among older patients with cancer and type 2 diabetes. The survival benefit persisted across various subgroups, including age, sex, and cancer type.
A cohort study found that GLP-1RAs like semaglutide and tirzepatide lower risk of dementia, stroke, and all-cause mortality in adults with type 2 diabetes and obesity. The findings suggest potential neuroprotective benefits beyond glycemic control.
A new study found significant reductions in medication use, symptoms, and procedural interventions with GLP-1 receptor agonist therapy for idiopathic intracranial hypertension. Further prospective studies are needed to confirm these findings.
The article provides practical strategies for managing symptoms in patients receiving GLP-1 RAs, focusing on diet and physical activity interventions to support muscle and nutrient preservation. Lifestyle factors remain crucial in GLP-1 RA treatment for effective weight management.
A team of researchers from The University of Osaka has made a breakthrough in weight loss treatment by developing a one-time genome editing approach that introduces a GLP-1 receptor agonist gene. This innovative method enables the body to produce its own weight-loss medication, reducing the need for regular injections.
The use of GLP-1 receptor agonists among diabetes patients is associated with a higher risk of developing incident neovascular age-related macular degeneration. Further research is needed to understand the underlying mechanisms and trade-offs between benefits and risks.
GLP1-RA treatment is associated with improvements in quality of life, restrained eating, and emotional eating behavior. The treatment also provides reassurance regarding its psychiatric safety profile.
A study by Helmholtz Munich researchers found that GIPR agonism and antagonism decrease body weight and food intake via different mechanisms. GIPR agonists use GABAergic neurons to exert their effect, while antagonists rely on the GLP-1 receptor signal.
The study estimates that expanded Medicare coverage for GLP-1RAs would increase access to these treatments and reduce obesity-related comorbidities. However, this would come with substantial costs over a decade, projected at $8 billion, highlighting the need for further price reductions and cost-saving strategies.
A new study in The Lancet Public Health finds that safer supply programs complement existing treatment options for people struggling with opioid use disorder. Safer supply programs provide pharmaceutical-grade opioids to reduce overdose rates, healthcare utilization, and costs.
A study published by the European Association for the Study of Obesity found that women are significantly more aware of and have a better understanding of obesity drugs like semaglutide and tirzepatide. Understanding tolerable side effects, effectiveness, and ability to maintain weight loss is crucial for people commencing treatment.
A recent study published in Current Neuropharmacology suggests a potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists and depression, particularly in individuals with low dopamine function. The authors urge caution and recommend genetic testing to identify individuals at risk before prescribing these medications.
A six-month study found that patients using GLP-1 and dual GLP-1/GIP receptor agonist therapy experienced minimal lean muscle mass loss as they lost weight. Regular resistance training, consistent protein intake, and close supervision by an expert obesity doctor were associated with better muscle retention.
Research reveals that GLP-1RAs and SGLT2i medications significantly reduce the risk of Alzheimer's disease and related dementias in people with type 2 diabetes. No significant difference was found between these two treatments.
A meta-analysis of randomized clinical trials found that glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a statistically significant reduction in all-cause dementia. Cardioprotective glucose-lowering therapies, however, did not show an overall reduction in dementia risk.
A study found that spending on GLP-1 RAs increased from 2018 to 2023, with the largest growth rate between 2022 and 2023. The total spending on these medications exceeded $71 billion.
A study published in Diabetes, Obesity and Metabolism found that obesity rates among type 1 diabetes patients increased for all age groups and ethnicities from 2008 to 2023. GLP-1 receptor agonist use also rose sharply, with a sevenfold increase in severely obese youth with type 1 diabetes between 2008-11 and 2020-23.
A study found no increased risk of suicidal events among adults taking GLP-1 receptor agonists for diabetes or obesity, but continued monitoring is warranted to identify at-risk patients. The findings ease concerns about these potential adverse effects, allowing extended use of GLP-1 RAs.
A cohort study found no significant association between preoperative GLP-1 RA use and short-term postoperative aspiration pneumonia. The study suggests reassessing preoperative withholding guidelines for GLP-1 RAs. Researchers hope this finding can help alleviate growing concerns about adverse effects of these medications after surgery.